Northern Trust Corp Purchases Shares of 102,828 CeriBell (NASDAQ:CBLL)

Northern Trust Corp bought a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 102,828 shares of the company's stock, valued at approximately $2,661,000. Northern Trust Corp owned 0.29% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. FMR LLC bought a new stake in CeriBell during the fourth quarter worth $128,120,000. Vanguard Group Inc. bought a new stake in shares of CeriBell during the 4th quarter worth $18,015,000. Board of Trustees of The Leland Stanford Junior University acquired a new stake in CeriBell in the fourth quarter valued at about $16,143,000. Franklin Resources Inc. bought a new position in CeriBell in the fourth quarter valued at about $12,460,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in CeriBell during the fourth quarter worth about $10,750,000.

Analyst Ratings Changes

Several brokerages recently issued reports on CBLL. LADENBURG THALM/SH SH initiated coverage on shares of CeriBell in a report on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and set a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $32.50.

CeriBell Stock Performance

Shares of CeriBell stock traded up $0.19 during trading on Thursday, hitting $17.38. The company's stock had a trading volume of 43,645 shares, compared to its average volume of 267,259. CeriBell has a 52 week low of $10.01 and a 52 week high of $32.75. The stock has a 50-day moving average price of $16.94 and a two-hundred day moving average price of $21.92.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to the consensus estimate of $19.30 million. Sell-side analysts forecast that CeriBell will post -2.46 EPS for the current year.

Insider Buying and Selling at CeriBell

In other CeriBell news, CEO Xingjuan Chao sold 25,000 shares of the company's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $16.96, for a total transaction of $424,000.00. Following the sale, the chief executive officer now owns 727,151 shares of the company's stock, valued at approximately $12,332,480.96. This represents a 3.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders sold 49,700 shares of company stock valued at $796,434. 20.10% of the stock is currently owned by company insiders.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.